Table 3 Outcomes

From: Levosimendan for postoperative subclinical heart failure after noncardiac surgery: a randomized, double-blinded, phase III trial

 

Levosimendan

(n = 115)

Placebo

(n = 113)

p Value

Primary outcome

Maximum NT-proBNP,

1270 [704, 2363]

1304 [676, 2040]

0.902

Secondary outcome

Maximum, Troponin T, ng dL-1

26 [19,43]

24 [17,35]

0.085

MINS, n (%)

74 (64)

58 (51)

0.063

Exploratory outcome

MACE within 30 days, (%)

2 (1.7)

5 (4.3)

0.245

 

Myocardial Infarction, n (%)

0 (0)

2 (1.7)

 

Stroke, n (%)

0 (0)

0 (0)

 

Death, n (%)

2 (1.7)

3 (2.7)

 
  1. Summary characteristics are presented as counts (percentages) of patients within groups, or median, quartiles [25th percentile; 75th percentile]. p values are from two-sided Wilcoxon-rank-sum tests, Chi-square or Fisher's exact test, as appropriate. A p value < 0.05 was considered as statistically significant. Due to the exploratory character of these analyses, no correction for multiplicity was performed.
Back to article page